Gene Biotherapeutics (Gene Biotherapeutics) Total Inventories : $0.00 Mil (As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Total Inventories?

Gene Biotherapeutics's total inventories for the quarter that ended in Dec. 2020 was $0.00 Mil. Gene Biotherapeutics's average total inventories from the quarter that ended in Sep. 2020 to the quarter that ended in Dec. 2020 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Gene Biotherapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2020 was $-0.10.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gene Biotherapeutics Total Inventories Historical Data

The historical data trend for Gene Biotherapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Total Inventories Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Inventories

Get a 7-Day Free Trial

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Gene Biotherapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Gene Biotherapeutics (OTCPK:CRXM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Gene Biotherapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2020 is

	Net-Net Working Capital Per Share (Q: Dec. 2020 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.386	+	0.75 * 0	+	0.5 * 0	-	5.135
-	0	-	-0.693)	/	40.3301
=	-0.10

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Gene Biotherapeutics's Days Inventory for the three months ended in Dec. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2020 )	/	Cost of Goods Sold (Q: Dec. 2020 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Gene Biotherapeutics's Inventory Turnover for the quarter that ended in Dec. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2020 )	/	Average Total Inventories (Q: Dec. 2020 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gene Biotherapeutics's Inventory to Revenue for the quarter that ended in Dec. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2020 )	/	Revenue (Q: Dec. 2020 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Gene Biotherapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010